Amsterdam, the Netherlands, November 16, 2007 – Schering-Plough Corporation has received antitrust clearance from the U.S. Federal Trade Commission (FTC) regarding its planned acquisition of Organon BioSciences N.V. (OBS) from Akzo Nobel N.V.
In connection with the conditional FTC clearance, Schering-Plough and the OBS animal health business, Intervet, will divest three poultry vaccines in the United States. No divestitures of human health products are required.
The EUR 11 billion deal was announced in March and Schering-Plough has already received approval for the transaction from the European Commission.
Akzo Nobel and Schering-Plough continue to expect the deal to be completed by the end of 2007.